AIMS: The Ross operation is the operation of choice for children who require aortic valve replacement (AVR) and may also provide a good option in selected adult patients. Although the autograft does not require anticoagulation and has a superior haemodynamic profile, concern regarding autograft and allograft longevity has risen. In this light, we report the 13-year results of our prospective autograft cohort study. METHODS AND RESULTS: Between 1988 and 2005, 146 consecutive patients underwent AVR with a pulmonary autograft at Erasmus Medical Center Rotterdam. Mean age was 22 years (SD 13; range 4 months-52 years), 66% were male. Hospital mortality was 2.7% (N = 4); during follow-up four more patients died. Thirteen-year survival was 94 +/- 2%. Over time, 22 patients required autograft reoperation for progressive neo-aortic root dilatation. In addition, eight patients required allograft reoperation. Freedom from autograft reoperation at 13 years was 69 +/- 7%. Freedom from allograft reoperation for structural failure at 13 years was 87 +/- 5%. Risk factors for autograft reoperation were previous AVR and adult patient age. CONCLUSION: Although survival of the Rotterdam autograft cohort is excellent, over time a worrisome increase in reoperation rate is observed. Given the progressive autograft dilatation, careful follow-up of these patients is warranted in the second decade after operation.
AIMS: The Ross operation is the operation of choice for children who require aortic valve replacement (AVR) and may also provide a good option in selected adult patients. Although the autograft does not require anticoagulation and has a superior haemodynamic profile, concern regarding autograft and allograft longevity has risen. In this light, we report the 13-year results of our prospective autograft cohort study. METHODS AND RESULTS: Between 1988 and 2005, 146 consecutive patients underwent AVR with a pulmonary autograft at Erasmus Medical Center Rotterdam. Mean age was 22 years (SD 13; range 4 months-52 years), 66% were male. Hospital mortality was 2.7% (N = 4); during follow-up four more patients died. Thirteen-year survival was 94 +/- 2%. Over time, 22 patients required autograft reoperation for progressive neo-aortic root dilatation. In addition, eight patients required allograft reoperation. Freedom from autograft reoperation at 13 years was 69 +/- 7%. Freedom from allograft reoperation for structural failure at 13 years was 87 +/- 5%. Risk factors for autograft reoperation were previous AVR and adult patient age. CONCLUSION: Although survival of the Rotterdam autograft cohort is excellent, over time a worrisome increase in reoperation rate is observed. Given the progressive autograft dilatation, careful follow-up of these patients is warranted in the second decade after operation.
Authors: Vera Regitz-Zagrosek; Christa Gohlke-Bärwolf; Annette Geibel-Zehender; Markus Haass; Harald Kaemmerer; Irmtraut Kruck; Christoph Nienaber Journal: Clin Res Cardiol Date: 2008-09 Impact factor: 5.460
Authors: Amine Mazine; Rodolfo V Rocha; Ismail El-Hamamsy; Maral Ouzounian; Bobby Yanagawa; Deepak L Bhatt; Subodh Verma; Jan O Friedrich Journal: JAMA Cardiol Date: 2018-10-01 Impact factor: 14.676
Authors: Francesco Nappi; Sanjeet Singh Avtaar Singh; Mario Lusini; Antonio Nenna; Ivancarmine Gambardella; Massimo Chello Journal: Ann Transl Med Date: 2019-09
Authors: Markus Liebrich; Efstratios I Charitos; Christoph Dingemann; Detlef Roser; Joerg Seeburger; Wolfgang Hemmer; Vladimir Voth Journal: Ann Cardiothorac Surg Date: 2021-07
Authors: Andrew J Gorton; Eric P Anderson; Jonathan A Reimer; Khaled Abdelhady; Raed Sawaqed; Malek G Massad Journal: Pediatr Cardiol Date: 2021-05-28 Impact factor: 1.655
Authors: Philip J Kilner; Tal Geva; Harald Kaemmerer; Pedro T Trindade; Juerg Schwitter; Gary D Webb Journal: Eur Heart J Date: 2010-01-11 Impact factor: 29.983
Authors: Peter D Skillington; M Mostafa Mokhles; William Wilson; Leeanne Grigg; Marco Larobina; Michael O'Keefe; Johanna Takkenberg Journal: Glob Cardiol Sci Pract Date: 2013-12-30